Sectra AB (publ)

DB:61L0 Stock Report

Market Cap: €4.4b

Sectra Valuation

Is 61L0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 61L0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 61L0 (€22.82) is trading above our estimate of fair value (€16.96)

Significantly Below Fair Value: 61L0 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 61L0?

Key metric: As 61L0 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 61L0. This is calculated by dividing 61L0's market cap by their current earnings.
What is 61L0's PE Ratio?
PE Ratio133.1x
EarningsSEK 384.43m
Market CapSEK 51.16b

Price to Earnings Ratio vs Peers

How does 61L0's PE Ratio compare to its peers?

The above table shows the PE ratio for 61L0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.2x
NXU Nexus
44.1x17.1%€1.2b
COP CompuGroup Medical SE KGaA
45.2x30.5%€1.1b
AFX Carl Zeiss Meditec
23.7x16.0%€4.2b
M3V MeVis Medical Solutions
8xn/a€45.9m
61L0 Sectra
133.1x28.5%€51.2b

Price-To-Earnings vs Peers: 61L0 is expensive based on its Price-To-Earnings Ratio (133.1x) compared to the peer average (30.2x).

Price to Earnings Ratio vs Industry

How does 61L0's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
61L0 133.1xIndustry Avg. 34.0xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 61L0 is expensive based on its Price-To-Earnings Ratio (133.1x) compared to the Global Healthcare Services industry average (34x).

Price to Earnings Ratio vs Fair Ratio

What is 61L0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

61L0 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio133.1x
Fair PE Ratio31x

Price-To-Earnings vs Fair Ratio: 61L0 is expensive based on its Price-To-Earnings Ratio (133.1x) compared to the estimated Fair Price-To-Earnings Ratio (31x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 61L0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€22.82
€24.70
+8.2%
15.8%€28.60€20.80n/a2
Jan ’26€23.88
€24.70
+3.4%
15.8%€28.60€20.80n/a2
Oct ’25€24.54
€15.52
-36.8%
35.2%€20.98€10.06n/a2
Sep ’25€21.00
€14.85
-29.3%
31.3%€19.50€10.19n/a2
Aug ’25€20.64
€14.85
-28.1%
31.3%€19.50€10.19n/a2
Jul ’25€21.08
€14.85
-29.6%
31.3%€19.50€10.19n/a2
Jun ’25€20.88
€13.13
-37.1%
23.3%€16.19€10.07n/a2
May ’25€18.64
€13.13
-29.6%
23.3%€16.19€10.07n/a2
Apr ’25€17.94
€13.13
-26.8%
23.3%€16.19€10.07n/a2
Mar ’25€18.89
€12.70
-32.7%
19.3%€15.16€10.25n/a2
Feb ’25€17.15
€12.70
-25.9%
19.3%€15.16€10.25n/a2
Jan ’25€16.29
€11.39
-30.1%
9.8%€12.50€10.27€23.882
Dec ’24€11.76
€11.18
-4.9%
5.7%€11.81€10.55€24.482
Nov ’24€10.36
€11.18
+7.9%
5.7%€11.81€10.55€24.102
Oct ’24€11.06
€11.18
+1.1%
5.7%€11.81€10.55€24.542
Sep ’24€14.15
€11.21
-20.8%
5.7%€11.84€10.57€21.002
Aug ’24€14.13
€11.21
-20.7%
5.7%€11.84€10.57€20.642
Jul ’24€15.22
€11.03
-27.6%
2.0%€11.24€10.81€21.082
Jun ’24€15.42
€11.28
-26.8%
2.0%€11.50€11.06€20.882
May ’24€14.11
€11.28
-20.1%
2.0%€11.50€11.06€18.642
Apr ’24€14.57
€11.28
-22.6%
2.0%€11.50€11.06€17.942

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 13:51
End of Day Share Price 2025/01/07 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sectra AB (publ) is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Bjorn RydellABG Sundal Collier Sponsored
Mikael LöfdahlCarnegie Investment Bank AB